Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | RXRA | P19793 | 9/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 6/20 | 0.40 |
| ▸ | RXRB | P28702 | 5/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 4/20 | 0.39 |
| ▸ | RARG | P13631 | 4/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541564 | 0.86 | ALDH1A1 (0.46) | ALDH1A1RXRAHPGDTDP1MAPT | |
| SCHEMBL6542845 | 0.85 | GAA (0.46) | ALDH1A1RXRAHPGDMAPTHNF4A | |
| SCHEMBL6542841 | 0.85 | GAA (0.46) | ALDH1A1RXRAHPGDMAPTHNF4A | |
| SCHEMBL6542688 | 0.83 | RXRA (0.52) | ALDH1A1RXRARXRGRXRBRARB | |
| SCHEMBL5865467 | 0.82 | RXRA (0.43) | RXRARXRGRXRBRARBRARG | |
| SCHEMBL7461958 | 0.82 | IGF1R (0.59) | RXRAHPGD | |
| SCHEMBL7461962 | 0.82 | IGF1R (0.59) | RXRAHPGD | |
| SCHEMBL6543042 | 0.79 | RXRA (0.58) | ALDH1A1RXRARXRGRXRBKDM4E | |
| SCHEMBL5485141 | 0.79 | RXRA (0.49) | ALDH1A1RXRAHPGDTDP1MAPT | |
| SCHEMBL5486511 | 0.76 | RXRA (0.71) | ALDH1A1RXRAHPGDTDP1RXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421061-A4 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INC (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1214305-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016123-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | ALDH1A1 643/4885RXRA 793/4885HPGD 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.